Literature DB >> 33425965

Association of Cigarette Smoking, COPD, and Lung Cancer With Expression of SARS-CoV-2 Entry Genes in Human Airway Epithelial Cells.

Junping Yin1, Brigitte Kasper1, Frank Petersen1, Xinhua Yu1.   

Abstract

SARS-CoV-2 enters into human airway epithelial cells via membrane fusion or endocytosis, and this process is dependent on ACE2, TMPRSS2, and cathepsin L. In this study, we examined the expression profiles of the three SARS-CoV-2 entry genes in primary human airway epithelial cells isolated from smokers, non-smokers, patients with chronic obstructive pulmonary disease or lung cancer. An exhaustive search of the GEO database was performed to identify eligible data on 1st June 2020. In total, 46 GEO datasets comprising transcriptomic data of 3,053 samples were identified as eligible data for further analysis. All meta-analysis were performed using RStudio. Standardized mean difference was utilized to assess the effect size of a factor on the expression of targeted genes and 95% confidence intervals (CIs) were calculated. This study revealed that (i) cigarette smoking is associated with an increased expression of ACE2 and TMPRSS2 and a decreased expression of cathepsin L; (ii) significant alternations in expression of ACE2, TMPRSS2, and cathepsin L were observed between current smokers and former smokers, but not between former smokers and never smokers; (iii) when compared with healthy controls with identical smoking status, patients with COPD or lung cancer showed negligible changes in expression of ACE2, TMPRSS2, and cathepsin L. Therefore, this study implicates cigarette smoking might contribute to the development of COVID-19 by affecting the expression of SARS-CoV-2 entry genes, while smoking cessation could be effective to reduce the potential risk.
Copyright © 2020 Yin, Kasper, Petersen and Yu.

Entities:  

Keywords:  ACE2 (angiotensin converting enzyme-2); COVID-19; SARS-CoV-2; cathpesin L; human airway epithelial cells; smoking; transmembrane serine protease 2

Year:  2020        PMID: 33425965      PMCID: PMC7793919          DOI: 10.3389/fmed.2020.619453

Source DB:  PubMed          Journal:  Front Med (Lausanne)        ISSN: 2296-858X


  6 in total

1.  Transmembrane serine protease 2 is a prognostic factor for lung adenocarcinoma.

Authors:  Marc A Schneider; Sarah Richtmann; Anna R Gründing; Sabine Wrenger; Tobias Welte; Michael Meister; Mark Kriegsmann; Hauke Winter; Thomas Muley; Sabina Janciauskiene
Journal:  Int J Oncol       Date:  2022-02-25       Impact factor: 5.650

Review 2.  The immune response to COVID-19: Does sex matter?

Authors:  Jim Q Ho; Mohammad Reza Sepand; Banafsheh Bigdelou; Tala Shekarian; Rahim Esfandyarpour; Prashant Chauhan; Vahid Serpooshan; Lalit K Beura; Gregor Hutter; Steven Zanganeh
Journal:  Immunology       Date:  2022-05-03       Impact factor: 7.215

3.  Air exposure and cell differentiation are essential for investigation of SARS-CoV-2 entry genes in human primary airway epithelial cells in vitro.

Authors:  Brigitte Kasper; Xiaoyang Yue; Torsten Goldmann; Askin Gülsen; Christian Kugler; Xinhua Yu; Frank Petersen
Journal:  Front Med (Lausanne)       Date:  2022-09-06

4.  Smoking and COVID-19 Infection and Related Mortality: A Prospective Cohort Analysis of UK Biobank Data.

Authors:  Albert Prats-Uribe; Junqing Xie; Daniel Prieto-Alhambra; Irene Petersen
Journal:  Clin Epidemiol       Date:  2021-05-25       Impact factor: 5.814

Review 5.  Challenges posed by COVID-19 in cancer patients: A narrative review.

Authors:  Zeinab Mohseni Afshar; Rezvan Hosseinzadeh; Mohammad Barary; Soheil Ebrahimpour; Amirmasoud Alijanpour; Babak Sayad; Dariush Hosseinzadeh; Seyed Rouhollah Miri; Terence T Sio; Mark J M Sullman; Kristin Carson-Chahhoud; Arefeh Babazadeh
Journal:  Cancer Med       Date:  2021-12-23       Impact factor: 4.711

6.  Multi-omics of the expression and clinical outcomes of TMPRSS2 in human various cancers: A potential therapeutic target for COVID-19.

Authors:  Li Liu; Ju-Fang Qin; Man-Zhen Zuo; Quan Zhou
Journal:  J Cell Mol Med       Date:  2021-12-24       Impact factor: 5.310

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.